108 related articles for article (PubMed ID: 19304437)
1. Killing of Escherichia coli by beta-lactams at different inocula.
Tam VH; Ledesma KR; Chang KT; Wang TY; Quinn JP
Diagn Microbiol Infect Dis; 2009 Jun; 64(2):166-71. PubMed ID: 19304437
[TBL] [Abstract][Full Text] [Related]
2. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
3. Bactericidal activity of ertapenem against major intra-abdominal pathogens.
Borbone S; Cascone C; Santagati M; Mezzatesta ML; Stefani S
Int J Antimicrob Agents; 2006 Nov; 28(5):396-401. PubMed ID: 17045463
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
[TBL] [Abstract][Full Text] [Related]
5. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
6. Susceptibilities of ESBL-producing Enterobacteriaceae to ertapenem, meropenem and piperacillin-tazobactam with and without clavulanic acid.
Raveh D; Yinnon AM; Broide E; Rudensky B
Chemotherapy; 2007; 53(3):185-9. PubMed ID: 17347564
[TBL] [Abstract][Full Text] [Related]
7. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of piperacillin/tazobactam and ertapenem against Bacteroides fragilis and Escherichia coli in pure and mixed cultures.
Valéria Dos Santos K; Diniz CG; Coutinho SC; Apolônio ACM; Geralda de Sousa-Gaia L; Nicoli JR; Farias LM; Roque de Carvalho MA
J Med Microbiol; 2007 Jun; 56(Pt 6):798-802. PubMed ID: 17510265
[TBL] [Abstract][Full Text] [Related]
9. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
10. Inoculum effect on the efficacies of amoxicillin-clavulanate, piperacillin-tazobactam, and imipenem against extended-spectrum β-lactamase (ESBL)-producing and non-ESBL-producing Escherichia coli in an experimental murine sepsis model.
Docobo-Pérez F; López-Cerero L; López-Rojas R; Egea P; Domínguez-Herrera J; Rodríguez-Baño J; Pascual A; Pachón J
Antimicrob Agents Chemother; 2013 May; 57(5):2109-13. PubMed ID: 23439636
[TBL] [Abstract][Full Text] [Related]
11. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
[TBL] [Abstract][Full Text] [Related]
13. Impact of tazobactam pharmacokinetics on the antimicrobial effect of piperacillin-tazobactam combinations.
Liu Q; Rand K; Derendorf H
Int J Antimicrob Agents; 2004 May; 23(5):494-7. PubMed ID: 15120729
[TBL] [Abstract][Full Text] [Related]
14. In vitro efficacy of ceftriaxone/sulbactam against Escherichia coli isolates producing CTX-M-15 extended-spectrum beta-lactamase.
Shahid M; Singhai M; Malik A; Shukla I; Khan HM; Shujatullah F; Tahira F
J Antimicrob Chemother; 2007 Jul; 60(1):187-8. PubMed ID: 17491002
[No Abstract] [Full Text] [Related]
15. In vitro antimicrobial activity of piperacillin/tazobactam in comparison with other broad-spectrum beta-lactams.
Roland RK; Mendes RE; Silbert S; Bolsoni AP; Sader HS
Braz J Infect Dis; 2000 Oct; 4(5):226-35. PubMed ID: 11063554
[TBL] [Abstract][Full Text] [Related]
16. In vitro pharmacodynamic evaluation of ceftolozane/tazobactam against β-lactamase-producing Escherichia coli in a hollow-fibre infection model.
Soon RL; Lenhard JR; Bulman ZP; Holden PN; Kelchlin P; Steenbergen JN; Friedrich LV; Forrest A; Tsuji BT
Int J Antimicrob Agents; 2017 Jan; 49(1):25-30. PubMed ID: 27931793
[TBL] [Abstract][Full Text] [Related]
17. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
Livermore DM; Mushtaq S; Nguyen T; Warner M
Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
[TBL] [Abstract][Full Text] [Related]
18. Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Bedenic B; Vranes J; Suto S; Zagar Z
Int J Antimicrob Agents; 2005 Jun; 25(6):479-87. PubMed ID: 15894465
[TBL] [Abstract][Full Text] [Related]
19. Antibiotic policy and prescribing strategies for therapy of extended-spectrum beta-lactamase-producing Enterobacteriaceae: the role of piperacillin-tazobactam.
Peterson LR
Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():181-4. PubMed ID: 18154544
[TBL] [Abstract][Full Text] [Related]
20. In the literature. Piperacillin-tazobactam and extended-spectrum β-lactamase--producing Escherichia coli.
Clin Infect Dis; 2013 Nov; 57(10):iii-iv. PubMed ID: 24308040
[No Abstract] [Full Text] [Related]
[Next] [New Search]